Try Alerts Free   |   Login
Health Care › Pharmaceutical Preparations

Cellectar Biosciences (CLRB) Financials and Smart Investor 13F Alerts

See how revenue, income, cash flow, and balance sheet financials have changed over 33 quarters since 2012. Compare with CLRB stock chart to see long term trends.

CLRB stock compared to

CLRB Income Statement

Research & Development Expense:2375008
Total Operating Expenses:3799523
Operating Income:-3799523
Net Income:-3615076
Earnings Per Share, Basic:0.07
Shares Outstanding, Basic Avg:19812659

CLRB Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:35924
Net Cash from Operations:-3868709
Net Cash from Financing Activities:42209352
Property, Plant & Equipment Purchases:17210
Net Cash from Investing Activities:-17210
Net Change in Cash & Equivalents:38323433

CLRB Balance Sheet

Cash and Cash Equivalents:57165377
Total Current Assets:57939809
Property, Plant & Equipment, Net:355982
Total Assets:58659370
Accounts Payable:1429000
Total Short-Term Liabilities:3563101
Total Liabilities:3864841

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Boxer Capital, LLC
920,000 sh
 
$1,141
Renaissance Technologies LLC
441,327 sh
-349,275 sh
-44%
$547
-$465
Vanguard Group Inc
70,837 sh
54,082 sh
323%
$88
$67
Northern Trust Corp
25,085 sh
25,085 sh
NEW
$31
$31
Morgan Stanley
2,219 sh
-2 sh
0%
$3
Blackrock Inc.
59 sh
 
$0
Proequities, Inc.
0 sh
 
$0

Data imported from Cellectar Biosciences Inc SEC filings. Check original filings before making any investment decision.